What is the latest published BIO stock rating?

Bio-Rad Laboratories, Inc. is shown with Sell in the latest published report, analyzed 2026-10-14. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BIO analysis?

The full latest published report, analyzed 2026-10-14, lives at /stocks/BIO/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BIO?

The latest published report analyzed 2026-10-14 gives BIO a fair value of USD 165 and a potential value of USD 195. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BIO page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-14). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BIO Stock: Fundamentals & Analysis | StockMarketAgent.AI

Войти Start free

Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · USD

—

StockMarketAgent Research · Analyzed 2026-10-14

Our latest published analysis: BIO rated Sell

Bio-Rad Laboratories, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$165 / share

Potential value

$195 / share

Upside to FV

-54.5%

Moat

6/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$9.7B
P/E (forward)	41.3x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 41.3x
Market cap: $9.7B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$2.92B	$2.80B	$2.67B	$2.57B	$2.58B	-3.0%
Gross profit	$1.64B	$1.57B	$1.43B	$1.38B	$1.34B	-4.9%
Operating income	$500.3M	$482.6M	$337.8M	$269.0M	$47.2M	-44.6%
Net income	$4.25B	$-3.63B	$-637.3M	$-1.84B	$759.9M	-35.0%
EPS (diluted)	$140.83	$-39.59	$-21.82	$-65.36	$27.85	-33.3%
EBITDA	$5.59B	$-4.53B	$-654.8M	$-2.14B	$1.21B	-31.8%
R&D	$260.6M	$256.9M	$247.4M	$295.9M	$275.6M	+1.4%
SG&A	$877.1M	$827.8M	$841.7M	$814.0M	$844.3M	-0.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	Продавать
ABNB	Airbnb, Inc.	—	—	—	—	—	—	Продавать
ADBE	Adobe Inc.	—	—	—	—	—	—	Активно покупать
ABBV	AbbVie Inc.	—	—	—	—	—	—	Продавать
ABT	Abbott Laboratories	—	—	—	—	—	—	Сокращать
ALGN	Align Technology Inc.	—	—	—	—	—	—	Сокращать

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($164.82). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
8.5%	$177	$180	$184	$188	$192
9.0%	$168	$171	$174	$177	$181
9.5%	$160	$162	$165	$168	$171
10.0%	$153	$155	$157	$159	$162
10.5%	$146	$148	$150	$152	$154

Scorecard

Published factor rows and weighted composite

Valuation1.5

Management6.5

Balance Sheet8.5

Profitability3.5

Revenue Growth2.5

Risk Assessment8.0

Competitive Moat6.0

Earnings Quality5.5

Capital Efficiency2.5

Weighted composite

4.9/10

Mixed

Category	Score	Reading
Valuation	1.5
Management	6.5
Balance Sheet	8.5
Profitability	3.5
Revenue Growth	2.5
Risk Assessment	8.0
Competitive Moat	6.0
Earnings Quality	5.5
Capital Efficiency	2.5

История рейтингов

Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.

Год	янв.	февр.	март	апр.	май	июнь	июль	авг.	сент.	окт.	нояб.	дек.
2026

Продавать

Bio-Rad Laboratories, Inc. (BIO)

Our latest published analysis: BIO rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · BIO

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on BIO

Frequently asked questions

История рейтингов